Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06318559
Other study ID # 027-FPO22
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 29, 2022
Est. completion date December 31, 2027

Study information

Verified date March 2024
Source Fondazione del Piemonte per l'Oncologia
Contact Enrico Checcucci, MD
Phone +390119933632
Email enrico.checcucci@ircc.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective randomized multicenter study aimed at comparing 3D AI-AR-RARP vs. no 3D, verifying the impact of this new technology on oncological and functional outcomes after the procedure.


Description:

Considering that prostate cancer lesions are not identifiable during surgery, except in the case of extensive and advanced tumors, the surgeon does not have a real-time perception of the location of the tumor. The absence of clear spatial visualization can therefore lead to a positive surgical margin, particularly in tumors in the T3 stage (invasion of the prostatic capsule or seminal vesicles). Our hypothesis is that with the help of AI 3D AR during surgery, positive surgical margins can be avoided, or at least reduced, while preserving the neurovascular bundles, with a consequent improvement not only in postoperative functional outcomes (continence and potency), but also oncological ones (less biochemical disease recovery (BCR), less need for salvage radiotherapy, lower risk of metastasis).


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date December 31, 2027
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender Male
Age group 40 Years to 99 Years
Eligibility Inclusion Criteria: 1. Signature of the written informed consent and consent to the use of personal data 2. Age > 40 years and male sex 3. Pre-operative MRI performed according to ESUR recommendations and reporting in accordance with PiRads V.2 4. Disease with evidence of bulging or radiological T3 on pre-operative MRI 5. Histological diagnosis of acinar type prostate cancer in the area highlighted on MRI 6. Absence of bulky (>3 cm), bony or visceral retroperitoneal or pelvic lymph node metastatic lesions 7. Patients eligible for radical prostatectomy + pelvic lymphadenectomy 8. ECOG PS 0-1 9. Life expectancy = 5 years 10. Patients motivated to preserve erection and with pre-operative sexual activity with IIEF >17 11. Availability of the patient's pre-operative clinical data 12. Patients must be available to carry out the visits foreseen in the follow-up of the protocol and consent to data collection Exclusion Criteria: 1. Special histotypes of prostate cancer 2. Patients with PSA > 100 ng/ml at diagnosis 3. Inability to perform MRI (pacemaker wearers, claustrophobia...) or MRI of inadequate quality to obtain the HA3DTM 3D reconstruction 4. Concomitant treatment with other antineoplastic drugs including investigational endocrine therapies 5. Serious uncontrolled concomitant medical condition or disease including active, uncontrolled infections 6. Patients with dementia or psychiatric illness that limit compliance with study requirements or that may prevent understanding and/or signing informed consent.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
3D Robot-assisted laparoscopic radical prostatectomy and pelvic lymphadenectomy
The operation is performed using the "Da Vinci HD" robotic system which allows the use of laparoscopic instruments, with greater mobility and the possibility of easier and more precise control of movements in three dimensions. Furthermore, the system allows the surgeon a three-dimensional view of the operating field. The surgery is performed under general anesthesia. Six or more trocars are positioned, into which the instruments operated by the robot or directly by the surgical assistants are inserted. Then a radical prostatectomy is performed.

Locations

Country Name City State
Italy Fondazione del Piemonte per l'Oncologia-IRCCS Candiolo Candiolo Turin
Italy AOU san Luigi Gonzaga Orbassano Turin

Sponsors (2)

Lead Sponsor Collaborator
Fondazione del Piemonte per l'Oncologia San Luigi Gonzaga Hospital

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Other Verify the potential application of AI Verify the potential application of AI as an alert system during surgery in order to reduce the rate of possible intraoperative complications 12 months after surgery
Primary Perioperative surgical oncological outcomes Verify oncological outcomes in prostate cancer patients with evidence of bulging or extracapsular disease (ECE or rT3) on preoperative MRI, in terms of positive margin rate (PSM) following surgery 12 months after surgery
Secondary Micturition outcomes Evaluation of continence recovery rate. Continence was defined as use of 0-1 pads/die. Furthermore 24/h pad test was performed in case of persistence of incontinence to evaluate the different degree of urine losses, and was classified according to ICS definitions. 5 years after surgery
Secondary Sexual function outcomes Evaluation of erection recovery in terms of IIEF-5 (International Index of Erectile Function Questionnaire). 5 years after surgery
Secondary Oncological outcomes Evaluation of patients' oncological outcomes during the follow up in terms of biochemical recurrence (BCR) and occurrence of local/distant recurrence detected with different imaging techniques during the FU according to clinical indication 5 years after surgery
See also
  Status Clinical Trial Phase
Withdrawn NCT05191017 - Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC Phase 1/Phase 2
Completed NCT00970203 - Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer Phase 2
Completed NCT03031418 - Clinical Evaluation of the 'ExoDx Prostate IntelliScore' (EPI)
Completed NCT01639859 - Assessment of Supersonic Imagine Aixplorer for the Detection and Localisation of Prostate Cancer Foci N/A
Not yet recruiting NCT06406803 - The Impact of Physical Activity Versus Dietary Energy Restriction on Tumour and Muscle Protein Synthesis in Prostate Cancer Patients N/A
Completed NCT02362464 - Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139 Phase 2
Enrolling by invitation NCT05844761 - Real-time Motion Management During Prostate and Lung Radiotherapy N/A
Completed NCT03442075 - Pain Comparison Whit Visual Analog Scale (EVA) Between Four Analgesic Methods During Trans Rectal Prostatic Biopsy
Recruiting NCT05252390 - NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03896958 - The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
Completed NCT03444532 - Feasibility Study Testing a Sleep Intervention in Prostate Cancer Patients With Insomnia N/A
Recruiting NCT05600400 - Improving Sexual Quality of Life - Randomized Trial of Two vs Five MRI Guided SABR Treatments for Prostate Cancer N/A
Recruiting NCT04887935 - Neoadjuvant SGLT2 Inhibition in High-Risk Localized Prostate Cancer Phase 1
Completed NCT02235142 - Prostatic Cancer Versus Androgen Deficiency N/A
Completed NCT01477749 - Sipuleucel-T Manufacturing Demonstration Study Phase 2
Active, not recruiting NCT03632980 - Dynamic Focusing Evaluation for Prostate Cancer Treatment N/A
Recruiting NCT04319783 - Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA Phase 2
Recruiting NCT04258813 - Onco-primary Care Networking to Support TEAM-based Care N/A
Recruiting NCT05361798 - T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy Phase 2
Completed NCT04304196 - Tailored, wEb-based, Psychosocial and Physical Activity Self-Management PrOgramme N/A